Moxetumomab pasudotox (Lumoxiti)

From HemOnc.org - A Hematology Oncology Wiki

Revision as of 21:51, 26 November 2014 by Jwarner (talk | contribs) (Created page with "=Mechanism of action= Antibody-drug conjugate targeted against CD22 =Preliminary data= ==Hairy cell leukemia== # Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, St...")

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Jump to navigation Jump to search

Mechanism of action

Antibody-drug conjugate targeted against CD22

Preliminary data

Hairy cell leukemia

Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, Fitzgerald DJ, Lechleider R, Pastan I. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol. 2012 May 20;30(15):1822-8. Epub 2012 Feb 21. PubMed

Also known as

CAT-8015

Retrieved from "https://hemonc.org/w/index.php?title=Moxetumomab_pasudotox_(Lumoxiti)&oldid=6158"